Interleukin-16 (IL-16) is a multifunctional cytokine that has been associated with autoimmune and allergic diseases. To investigate comprehensively whether IL-16 is also associated with chronic obstructive pulmonary disease (COPD) and emphysema, we performed an integrated analysis of multiple “omics” data. Over 500 subjects participating in the COPDGene® study donated blood and were clinically characterized and genetically profiled. IL-16 mRNA levels were measured in peripheral blood mononuclear cells (PBMC), and protein levels were measured in fresh frozen plasma. A multivariate analysis found plasma IL-16 positively associated with age and body mass index, and negatively associated with current smoking and emphysema in the upper lobes. PBMC IL-16 expression was positively associated with gender and a composite score for airflow obstruction, emphysema, and gas trapping. Whole-genome expression quantitative trait locus (eQTL) analysis identified a novel IL-16 missense SNP (rs11556218) associated with lower IL-16 in plasma. In summary, an integrated “omics” analysis in a very large cohort identified an association between decreased IL-16 and emphysema and discovered a novel IL-16 cis-eQTL. Thus IL-16 plasma levels and IL-16 genotyping may be useful in a personalized medicine approach for lung disease.
Get full access to this article
View all access options for this article.
References
1.
AkessonLS, DuffyDL, PhelpsSC, ThompsonPJ, KeddaMA. 2005. A polymorphism in the promoter region of the human interleukin-16 gene is not associated with asthma or atopy in an Australian population. Clin Exp Allergy, 35:327–331.
2.
AkiyamaK, KarakiM, KobayshiR, DobashiH, IshidaT, MoriN. 2009. IL-16 variability and modulation by antiallergic drugs in a murine experimental allergic rhinitis model. Int Arch Allergy Immunol, 149:315–322.
3.
AnderssonA, QvarfordtI, LaanMet al.2004. Impact of tobacco smoke on interleukin-16 protein in human airways, lymphoid tissue and T lymphocytes. Clin Exp Immunol, 138:75–82.
BaierM, BannertN, WernerA, LangK, KurthR. 1997. Molecular cloning, sequence, expression, and processing of the interleukin-16 precursor. Proc Natl Acad Sci USA, 94:5273–5277.
6.
BarnesPJ. 2006. Against the Dutch hypothesis: Asthma and chronic obstructive pulmonary disease are distinct diseases. Am J Respir Crit Care Med, 174:240–243discussion 243–244.
7.
BlaschkeS, SchulzH, SchwarzG, BlaschkeV, MullerGA, Reuss-BorstM. 2001. Interleukin-16 expression in relation to disease activity in rheumatoid arthritis. J Rheumatol, 28:12–21.
8.
BolstadBM, IrizarryRA, AstrandM, SpeedTP. 2003. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics, 19:185–193.
9.
BowlerRP, BarnesPJ, CrapoJD. 2004. The role of oxidative stress in chronic obstructive pulmonary disease. Copd, 1:255–277.
10.
BurkartKM, BartonSJ, HollowayJWet al.2006. Association of asthma with a functional promoter polymorphism in the IL16 gene. J Allergy Clin Immunol, 117:86–91.
11.
ChoMH, CastaldiPJ, WanESet al.2012. A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet, 21:947–957.
CruikshankWW, LongA, TarpyREet al.1995. Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am J Respir Cell Mol Biol, 13:738–747.
14.
de TorresJP, CasanovaC, Pinto-PlataVet al.2011. Gender differences in plasma biomarker levels in a cohort of COPD patients: A pilot study. PLoS ONE, 6:e16021.
15.
DuanH, FlemingJ, PritchardDKet al.2008. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum, 58:1465–1474.
16.
El BassamS, PinsonneaultS, KornfeldH, RenF, MenezesJ, LabergeS. 2006. Interleukin-16 inhibits interleukin-13 production by allergen-stimulated blood mononuclear cells. Immunology, 117:89–96.
17.
FabbriLM, HurdSS. 2003. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J, 22:1–2.
18.
FerlandC, FlamandN, DavoineF, ChakirJ, LavioletteM. 2004. IL-16 activates plasminogen-plasmin system and promotes human eosinophil migration into extracellular matrix via CCR3-chemokine-mediated signaling and by modulating CD4 eosinophil expression. J Immunol, 173:4417–4424.
19.
FrezzoliniA, CianchiniG, RuffelliM, CadoniS, PudduP, De PitaO. 2004. Interleukin-16 expression and release in bullous pemphigoid. Clin Exp Immunol, 137:595–600.
20.
GaoLB, RaoL, WangYYet al.2009. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis, 30:295–299.
21.
GhigoE, BarryAO, PretatLet al.2010. IL-16 promotes T. whipplei replication by inhibiting phagosome conversion and modulating macrophage activation. PLoS One, 5:e13561.
22.
GoihlA, RolleAM, KahneT, ReinholdA, WrengerS, ReinholdD. 2012. Methodologic issues in the measurement of interleukin-16 in clinical blood samples using immunoassays. Cytokine, 58:1–5.
23.
GuY, LewisSF, DeereK, GroomeLJ, WangY. 2008. Elevated maternal IL-16 levels, enhanced IL-16 expressions in endothelium and leukocytes, and increased IL-16 production by placental trophoblasts in women with preeclampsia. J Immunol, 181:4418–4422.
24.
HankinsonJL, OdencrantzJR, FedanKB. 1999. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med, 159:179–187.
25.
JinCZ, ZhaoY, ZhangFJet al.2009. Different plasma levels of interleukins and chemokines: Comparison between children and adults with AIDS in China. Chin Med J (Engl), 122:530–535.
26.
KaserA, DunzendorferS, OffnerFAet al.2000. B lymphocyte-derived IL-16 attracts dendritic cells and Th cells. J Immunol, 165:2474–2480.
27.
KaufmannJ, FrankeS, Kientsch-EngelR, OelznerP, HeinG, SteinG. 2001. Correlation of circulating interleukin-16 with proinflammatory cytokines in patients with rheumatoid arthritis. Rheumatology (Oxford), 40:474–475.
28.
KimYI, SchroederJ, LynchDet al.2011. Gender differences of airway dimensions in anatomically matched sites on CT in smokers. COPD, 8:285–292.
29.
KlimiukPA, GoronzyJJ, WeyandCM. 1999. IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol, 162:4293–4299.
30.
KrugN, CruikshankWW, TschernigTet al.2000. Interleukin-16 and T-cell chemoattractant activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma. Am J Respir Crit Care Med, 162:105–111.
31.
LabergeS, ErnstP, GhaffarOet al.1997. Increased expression of interleukin-16 in bronchial mucosa of subjects with atopic asthma. Am J Respir Cell Mol Biol, 17:193–202.
32.
LabergeS, GhaffarO, BoguniewiczM, CenterDM, LeungDY, HamidQ. 1998. Association of increased CD4+ T-cell infiltration with increased IL-16 gene expression in atopic dermatitis. J Allergy Clin Immunol, 102:645–650.
33.
LardLR, RoepBO, ToesRE, HuizingaTW. 2004. Enhanced concentrations of interleukin-16 are associated with joint destruction in patients with rheumatoid arthritis. J Rheumatol, 31:35–39.
34.
LardLR, RoepBO, VerburghCA, ZwindermanAH, HuizingaTW. 2002. Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus, 11:181–185.
LivakKJ, SchmittgenTD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods, 25:402–408.
38.
LokkeA, LangeP, ScharlingH, FabriciusP, VestboJ. 2006. Developing COPD: A 25 year follow up study of the general population. Thorax, 61:935–939.
MathyNL, ScheuerW, LanzendorferMet al.2000. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology, 100:63–69.
41.
McFaddenC, MorganR, RahangdaleSet al.2007. Preferential migration of T regulatory cells induced by IL-16. J Immunol, 179:6439–6445.
42.
MeagherC, BeilkeJ, ArreazaGet al.2010. Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism. Diabetes, 59:2862–2871.
43.
MottaM, ImbesiR, Di RosaM, StivalaF, MalaguarneraL. 2007. Altered plasma cytokine levels in Alzheimer's disease: Correlation with the disease progression. Immunol Lett, 114:46–51.
44.
PackardTA, LiQZ, CosgroveGP, BowlerRP, CambierJC. 2013. COPD is associated with production of autoantibodies to a broad spectrum of self-antigens, correlative with disease phenotype. Immunol Res, 55:48–57.
45.
PulleritsT, LindenA, MalmhallC, LotvallJ. 2001. Effect of seasonal allergen exposure on mucosal IL-16 and CD4+ cells in patients with allergic rhinitis. Allergy, 56:871–877.
46.
QiJC, WangJ, MandadiSet al.2006. Human and mouse mast cells use the tetraspanin CD9 as an alternate interleukin-16 receptor. Blood, 107:135–142.
47.
R Development Core Team. 2008. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
48.
ReganEA, HokansonJE, MurphyJRet al.2010. Genetic epidemiology of COPD (COPDGene) study design. COPD, 7:32–43.
49.
VandesompeleJ, De PreterK, PattynFet al.2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol, 3:RESEARCH0034.
50.
ZhangY, CenterDM, WuDMet al.1998. Processing and activation of pro-interleukin-16 by caspase-3. J Biol Chem, 273:1144–1149.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
